Protein Communication Pathway Identified as Vector for Alzheimer's Pathology

Alzheimer's disease is characterized by the accumulation of a toxic protein known as Tau, which systematically destroys brain cells, thereby causing progressive cognitive decline and memory loss. While Tau is present in all neurons, it aggregates during the disease into sticky tangles that disrupt the cell's internal transport mechanism. Postdoctoral researcher Dr. Mitali Tyagi compared these destructive tangles to 'glue monsters' that disintegrate into smaller seeds, which subsequently migrate to neighboring healthy cells and corrupt their native proteins.

In a groundbreaking study published in the journal Cell, neurobiologists at University of Utah Health investigated this transmission process using mouse models. They discovered that Arc, a protein crucial for communication between neurons, is utilized by toxic Tau to navigate from cell to cell. Normally, Arc packages itself into extracellular vesicles—microscopic membrane-bound sacs—to carry vital signals across synaptic clefts. However, the researchers demonstrated that toxic Tau attaches to Arc inside these vesicles, thereby exploiting the brain's communication system to spread disease.

By comparing mouse models with and without the protein, the team observed that when Arc was absent, the intercellular transfer of Tau was almost entirely eliminated. Notwithstanding this finding, the researchers discovered that Arc also performs a vital protective function by enabling damaged neurons to expel excess Tau and survive longer. Had Arc been completely absent, the sick cells would have succumbed to the rapid accumulation of intracellular Tau much more quickly. Consequently, intercepting the vesicles before they enter healthy neurons, rather than blocking their release, appears to be the most promising therapeutic strategy.

Although extracellular vesicles containing Arc and Tau were identified in human tissue, indicating this pathway is likely to exist in humans, clinical applications remain distant. Senior author Jason Shepherd emphasized that while the mouse data is encouraging, extensive human research is necessary before any therapy can be developed.